IMP1734 clinical trials

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study is testing a new drug, IMP1734, for people with advanced cancers. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumours. It's an early-stage study to gather information for future research.